Global Glioblastoma Multiforme (GBM) Therapeutics Market Size, Status and Forecast 2024-2031

Report ID: 1012190 | Published Date: Jan 2025 | No. of Page: 107 | Base Year: 2024 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 ChemOthersapy
        1.2.3 Targeted Drug Therapy
        1.2.4 Radiation Therapy
    1.3 Market by Application
        1.3.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Perspective (2016-2027)
    2.2 Glioblastoma Multiforme (GBM) Therapeutics Growth Trends by Regions
        2.2.1 Glioblastoma Multiforme (GBM) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Glioblastoma Multiforme (GBM) Therapeutics Historic Market Share by Regions (2016-2021)
        2.2.3 Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Regions (2022-2027)
    2.3 Glioblastoma Multiforme (GBM) Therapeutics Industry Dynamic
        2.3.1 Glioblastoma Multiforme (GBM) Therapeutics Market Trends
        2.3.2 Glioblastoma Multiforme (GBM) Therapeutics Market Drivers
        2.3.3 Glioblastoma Multiforme (GBM) Therapeutics Market Challenges
        2.3.4 Glioblastoma Multiforme (GBM) Therapeutics Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Revenue
        3.1.1 Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Revenue (2016-2021)
        3.1.2 Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Players (2016-2021)
    3.2 Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Glioblastoma Multiforme (GBM) Therapeutics Revenue
    3.4 Global Glioblastoma Multiforme (GBM) Therapeutics Market Concentration Ratio
        3.4.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Glioblastoma Multiforme (GBM) Therapeutics Revenue in 2020
    3.5 Glioblastoma Multiforme (GBM) Therapeutics Key Players Head office and Area Served
    3.6 Key Players Glioblastoma Multiforme (GBM) Therapeutics Product Solution and Service
    3.7 Date of Enter into Glioblastoma Multiforme (GBM) Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Glioblastoma Multiforme (GBM) Therapeutics Breakdown Data by Type
    4.1 Global Glioblastoma Multiforme (GBM) Therapeutics Historic Market Size by Type (2016-2021)
    4.2 Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Glioblastoma Multiforme (GBM) Therapeutics Breakdown Data by Application
    5.1 Global Glioblastoma Multiforme (GBM) Therapeutics Historic Market Size by Application (2016-2021)
    5.2 Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size (2016-2027)
    6.2 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type
        6.2.1 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021)
        6.2.2 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027)
        6.2.3 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2027)
    6.3 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application
        6.3.1 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021)
        6.3.2 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027)
        6.3.3 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2027)
    6.4 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country
        6.4.1 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021)
        6.4.2 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size (2016-2027)
    7.2 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type
        7.2.1 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021)
        7.2.2 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027)
        7.2.3 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2027)
    7.3 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application
        7.3.1 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021)
        7.3.2 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027)
        7.3.3 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2027)
    7.4 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country
        7.4.1 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021)
        7.4.2 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size (2016-2027)
    8.2 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type
        8.2.1 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2027)
    8.3 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application
        8.3.1 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2027)
    8.4 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region
        8.4.1 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size (2016-2027)
    9.2 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type
        9.2.1 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021)
        9.2.2 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027)
        9.2.3 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2027)
    9.3 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application
        9.3.1 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021)
        9.3.2 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027)
        9.3.3 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2027)
    9.4 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country
        9.4.1 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021)
        9.4.2 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size (2016-2027)
    10.2 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type
        10.2.1 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2027)
    10.3 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application
        10.3.1 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2027)
    10.4 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country
        10.4.1 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Merck
        11.1.1 Merck Company Details
        11.1.2 Merck Business Overview
        11.1.3 Merck Glioblastoma Multiforme (GBM) Therapeutics Introduction
        11.1.4 Merck Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
        11.1.5 Merck Recent Development
    11.2 Roche
        11.2.1 Roche Company Details
        11.2.2 Roche Business Overview
        11.2.3 Roche Glioblastoma Multiforme (GBM) Therapeutics Introduction
        11.2.4 Roche Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
        11.2.5 Roche Recent Development
    11.3 Arbor Pharmaceuticals
        11.3.1 Arbor Pharmaceuticals Company Details
        11.3.2 Arbor Pharmaceuticals Business Overview
        11.3.3 Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction
        11.3.4 Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
        11.3.5 Arbor Pharmaceuticals Recent Development
    11.4 Pfizer
        11.4.1 Pfizer Company Details
        11.4.2 Pfizer Business Overview
        11.4.3 Pfizer Glioblastoma Multiforme (GBM) Therapeutics Introduction
        11.4.4 Pfizer Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
        11.4.5 Pfizer Recent Development
    11.5 AbbVie
        11.5.1 AbbVie Company Details
        11.5.2 AbbVie Business Overview
        11.5.3 AbbVie Glioblastoma Multiforme (GBM) Therapeutics Introduction
        11.5.4 AbbVie Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
        11.5.5 AbbVie Recent Development
    11.6 Amgen
        11.6.1 Amgen Company Details
        11.6.2 Amgen Business Overview
        11.6.3 Amgen Glioblastoma Multiforme (GBM) Therapeutics Introduction
        11.6.4 Amgen Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
        11.6.5 Amgen Recent Development
    11.7 Bristol-Myers Squibb
        11.7.1 Bristol-Myers Squibb Company Details
        11.7.2 Bristol-Myers Squibb Business Overview
        11.7.3 Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Introduction
        11.7.4 Bristol-Myers Squibb Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
        11.7.5 Bristol-Myers Squibb Recent Development
    11.8 Sun Pharmaceuticals
        11.8.1 Sun Pharmaceuticals Company Details
        11.8.2 Sun Pharmaceuticals Business Overview
        11.8.3 Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction
        11.8.4 Sun Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
        11.8.5 Sun Pharmaceuticals Recent Development
    11.9 Teva Pharmaceutical
        11.9.1 Teva Pharmaceutical Company Details
        11.9.2 Teva Pharmaceutical Business Overview
        11.9.3 Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Introduction
        11.9.4 Teva Pharmaceutical Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
        11.9.5 Teva Pharmaceutical Recent Development
    11.10 Emcure Pharmaceuticals
        11.10.1 Emcure Pharmaceuticals Company Details
        11.10.2 Emcure Pharmaceuticals Business Overview
        11.10.3 Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction
        11.10.4 Emcure Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
        11.10.5 Emcure Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of ChemOthersapy
    Table 3. Key Players of Targeted Drug Therapy
    Table 4. Key Players of Radiation Therapy
    Table 5. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
    Table 8. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Regions (2016-2021)
    Table 9. Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 10. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Regions (2022-2027)
    Table 11. Glioblastoma Multiforme (GBM) Therapeutics Market Trends
    Table 12. Glioblastoma Multiforme (GBM) Therapeutics Market Drivers
    Table 13. Glioblastoma Multiforme (GBM) Therapeutics Market Challenges
    Table 14. Glioblastoma Multiforme (GBM) Therapeutics Market Restraints
    Table 15. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
    Table 16. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Players (2016-2021)
    Table 17. Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glioblastoma Multiforme (GBM) Therapeutics as of 2020)
    Table 18. Ranking of Global Top Glioblastoma Multiforme (GBM) Therapeutics Companies by Revenue (US$ Million) in 2020
    Table 19. Global 5 Largest Players Market Share by Glioblastoma Multiforme (GBM) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Glioblastoma Multiforme (GBM) Therapeutics Product Solution and Service
    Table 22. Date of Enter into Glioblastoma Multiforme (GBM) Therapeutics Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 25. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type (2016-2021)
    Table 26. Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 27. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 28. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
    Table 29. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Application (2016-2021)
    Table 30. Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 31. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 32. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 33. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 34. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 35. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 36. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 37. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 38. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 39. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 40. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 41. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 42. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 43. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 44. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 45. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 46. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 47. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 48. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2016-2021) & (US$ Million) 
    Table 49. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2022-2027) & (US$ Million) 
    Table 50. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 51. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 52. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 53. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 54. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 55. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 56. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 57. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 58. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 59. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 60. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 61. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 62. Merck Company Details
    Table 63. Merck Business Overview
    Table 64. Merck Glioblastoma Multiforme (GBM) Therapeutics Product
    Table 65. Merck Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
    Table 66. Merck Recent Development
    Table 67. Roche Company Details
    Table 68. Roche Business Overview
    Table 69. Roche Glioblastoma Multiforme (GBM) Therapeutics Product
    Table 70. Roche Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
    Table 71. Roche Recent Development
    Table 72. Arbor Pharmaceuticals Company Details
    Table 73. Arbor Pharmaceuticals Business Overview
    Table 74. Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product
    Table 75. Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
    Table 76. Arbor Pharmaceuticals Recent Development
    Table 77. Pfizer Company Details
    Table 78. Pfizer Business Overview
    Table 79. Pfizer Glioblastoma Multiforme (GBM) Therapeutics Product
    Table 80. Pfizer Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
    Table 81. Pfizer Recent Development
    Table 82. AbbVie Company Details
    Table 83. AbbVie Business Overview
    Table 84. AbbVie Glioblastoma Multiforme (GBM) Therapeutics Product
    Table 85. AbbVie Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
    Table 86. AbbVie Recent Development
    Table 87. Amgen Company Details
    Table 88. Amgen Business Overview
    Table 89. Amgen Glioblastoma Multiforme (GBM) Therapeutics Product
    Table 90. Amgen Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
    Table 91. Amgen Recent Development
    Table 92. Bristol-Myers Squibb Company Details
    Table 93. Bristol-Myers Squibb Business Overview
    Table 94. Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Product
    Table 95. Bristol-Myers Squibb Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
    Table 96. Bristol-Myers Squibb Recent Development
    Table 97. Sun Pharmaceuticals Company Details
    Table 98. Sun Pharmaceuticals Business Overview
    Table 99. Sun Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
    Table 100. Sun Pharmaceuticals Recent Development
    Table 101. Teva Pharmaceutical Company Details
    Table 102. Teva Pharmaceutical Business Overview
    Table 103. Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Product
    Table 104. Teva Pharmaceutical Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
    Table 105. Teva Pharmaceutical Recent Development
    Table 106. Emcure Pharmaceuticals Company Details
    Table 107. Emcure Pharmaceuticals Business Overview
    Table 108. Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product
    Table 109. Emcure Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
    Table 110. Emcure Pharmaceuticals Recent Development
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type: 2020 VS 2027
    Figure 2. ChemOthersapy Features
    Figure 3. Targeted Drug Therapy Features
    Figure 4. Radiation Therapy Features
    Figure 5. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application: 2020 VS 2027
    Figure 6. Hospitals Case Studies
    Figure 7. Clinics Case Studies
    Figure 8. Others Case Studies
    Figure 9. Glioblastoma Multiforme (GBM) Therapeutics Report Years Considered
    Figure 10. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 11. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 12. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Regions: 2020 VS 2027
    Figure 13. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Regions (2022-2027)
    Figure 14. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Players in 2020
    Figure 15. Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glioblastoma Multiforme (GBM) Therapeutics as of 2020
    Figure 16. The Top 10 and 5 Players Market Share by Glioblastoma Multiforme (GBM) Therapeutics Revenue in 2020
    Figure 17. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type (2016-2021)
    Figure 18. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type (2022-2027)
    Figure 19. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 20. North America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type (2016-2027)
    Figure 21. North America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application (2016-2027)
    Figure 22. North America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2016-2027)
    Figure 23. United States Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Canada Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type (2016-2027)
    Figure 27. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application (2016-2027)
    Figure 28. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2016-2027)
    Figure 29. Germany Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. France Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. U.K. Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Italy Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Russia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Nordic Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type (2016-2027)
    Figure 37. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application (2016-2027)
    Figure 38. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Share by Region (2016-2027)
    Figure 39. China Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Japan Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. South Korea Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Southeast Asia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. India Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Australia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type (2016-2027)
    Figure 47. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application (2016-2027)
    Figure 48. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2016-2027)
    Figure 49. Mexico Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Brazil Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type (2016-2027)
    Figure 53. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application (2016-2027)
    Figure 54. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2016-2027)
    Figure 55. Turkey Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Saudi Arabia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. UAE Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Merck Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
    Figure 59. Roche Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
    Figure 60. Arbor Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
    Figure 61. Pfizer Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
    Figure 62. AbbVie Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
    Figure 63. Amgen Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
    Figure 64. Bristol-Myers Squibb Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
    Figure 65. Sun Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
    Figure 66. Teva Pharmaceutical Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
    Figure 67. Emcure Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
    Figure 68. Bottom-up and Top-down Approaches for This Report
    Figure 69. Data Triangulation
    Figure 70. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Merck
Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceuticals
Teva Pharmaceutical
Emcure Pharmaceuticals
Frequently Asked Questions
Glioblastoma Multiforme (GBM) Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Glioblastoma Multiforme (GBM) Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Glioblastoma Multiforme (GBM) Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports